Ribavirin News and Research

RSS

Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

The immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species

Researchers characterized the immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species.

19 Jul 2023

Single mutation of the hepatitis E virus stands in the way of sofosbuvir drug's effectiveness

A single mutation stands in the way of a drug's effectiveness. Understanding it helps find new therapeutic approaches.

21 Jun 2023

Battle against RSV: Computational design paves way for new polyvalent vaccine

Research focuses on the design of a multi-epitope polyvalent vaccine against Human Respiratory Syncytial Virus (RSV), a leading cause of lower respiratory tract infections. The study utilizes computational methods and immunoinformatics tools to predict potential vaccine candidates and their interactions with Toll-like receptors (TLRs).

19 Jun 2023

Urgent call for improved diagnostics, treatments, and vaccines against deadly Hantavirus

Scientists discuss hantavirus infections, which are a type of viral hemorrhagic fever that can be transmitted to humans through exposure to infected rodents in endemic areas.

30 Apr 2023

A review of emerging pediatric respiratory viruses

Respiratory viruses continue to be a leading cause of childhood morbidity and mortality.

26 Oct 2022

Inhalation therapeutics against COVID-19

A recent study published in the Pulmonary Pharmacology & Therapeutics journal described different inhalation therapeutic agents for treating respiratory viral infections like coronavirus disease 2019 (COVID-19).

17 Oct 2022

Are men or women impacted more by adverse reactions to prescription drug treatments?

Recently, researchers presented an overview of sex-based differences in adverse drug reactions (ADRs) based on epidemiology, technique, and underlying mechanism data.

11 Oct 2022

RNA-dependent RNA polymerase inhibitors in COVID-19 therapy

A new paper reviews current knowledge of RdRp inhibitors that could be developed further to provide broadly effective antivirals against SARS-CoV-2 in particular and CoVs in general.

10 Oct 2022

Does Langya virus pose a spillover threat?

Researchers assess the potential impact of the Langya virus, its current risk, and what measures might help to contain this virus.

30 Aug 2022

Study provides insights into understanding the biology of circulating Hepatitis E variants

Over three million people are infected with the hepatitis E virus every year. So far, no effective treatment is available. An international team has investigated which factors are important for the virus in the course of its replication cycle and how it manages to maintain the infection.

17 Aug 2022

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

Researchers introduced a phenotypic screening assay for identifying compounds with SARS-CoV-2 inhibition potential based on caspase 3/7 activation.

20 Jul 2022

Nitazoxanide drug found to be a potent inhibitor of several human coronaviruses

Researchers evaluated the activity of nitazoxanide against human coronaviruses (HCoVs).

18 Jul 2022

What are the biological features, prevention and control strategies against monkeypox?

Researchers elucidated the epidemiology and clinical presentation, biological features, pathogenicity and prevention and control strategies for monkeypox virus (MPXV) infections.

13 Jul 2022

Chemically modified rocaglates have a stronger effect against viral replication

Hepatitis E virus (HEV) is widespread, and so far there is no effective drug. In the search for one, the so-called rocaglates have come into focus: plant compounds that can inhibit the replication of viruses.

27 Jun 2022

Probenecid shows activity against respiratory syncytial virus

A new study describes the antiviral activity of the approved drug probenecid against respiratory syncytial virus.

29 Apr 2022

Novel targets to inhibit SARS-CoV-2 variants

A new study identified additional targets on SARS-CoV-2 proteins to prevent the emergence of new SARS-CoV-2 variants of concern.

16 Mar 2022

Trial of early antiviral therapy for COVID-19 shows no significant benefit

A new preprint research paper examines the efficacy of using three antivirals in various combinations in early infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Feb 2022

Study explains why Omicron infections are less likely to cause severe disease

A new study by researchers from the University of Kent and the Goethe University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defense mechanism against viruses, the so-called “interferon response”.

24 Jan 2022

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

Screening FDA-approved compounds shown to possess antiviral or antimicrobial activity for SARS-CoV-2 inhibition

Researchers have screened several compounds that could show the ability to inhibit SARS-CoV-2.

10 Dec 2021